On Tuesday, Shares of Southern Co (NYSE:SO), gained 0.98% to $44.45.
The Mississippi Public Service Commission approved the largest solar installations in Mississippi, making Mississippi Power the largest partner in renewable energy in the state.
Mississippi Power is collaborating with three solar energy businesses and the U.S. Navy to build 105 MW of utility-scale solar electric generating farms at three different locations in the company’s service territory.
“These cost-effective, utility-scale solar energy projects once again place Mississippi Power at the forefront of the state’s energy economy by adding renewable energy into the company’s portfolio,” said Mississippi Power President Anthony Wilson. “Working together with our partners, these projects will have a substantial impact on the amount of electricity generated by renewables in Mississippi.”
The Southern Company, together with its auxiliaries, operates as a public electric utility company. It is involved in the generation, transmission, and distribution of electricity through coal, nuclear, oil and gas, and hydro resources in the states of Alabama, Georgia, Florida, and Mississippi.
Shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), declined -9.06% to $8.93, during its last trading session.
Merrimack Pharmaceuticals, declared its third quarter 2015 financial results. Merrimack will host a live conference call and webcast recently, Monday, November 9 at 4:30 p.m., Eastern time, to provide an update on Merrimack’s progress in addition to a summary of these results.
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development comprise MM-398, a nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is has accomplished Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer whose cancer had progressed on treatment with the chemotherapy drug gemcitabine; in a Phase I clinical trial as a monotherapy in patients with glioma and in combination with cyclophosphamide in patients with pediatric solid tumors; and in a Phase 1 translational clinical trial designed to identify predictive biomarkers associated with MM-398.
Finally, Shares of Youku Tudou Inc (ADR) (NYSE:YOKU), ended its last trade with 0.46% gain, and closed at $26.49.
Alibaba Group Holding Limited (BABA) and Youku Tudou Inc. (YOKU) today announced their entry into a definitive merger agreement pursuant to which an affiliate of Alibaba Group (“Alibaba”) will acquire Youku Tudou Inc., a leading multi-screen entertainment and media company in China (“Youku Tudou”), in an all-cash transaction (the “Transaction”).
Upon completion of the Transaction, the shareholders of Youku Tudou, other than the current investment entity controlled by Alibaba, will have the right to receive US$27.60 per American Depositary Share (“ADS”, each representing 18 ordinary shares of Youku Tudou) in cash. The price represents a premium of 35.1% over the closing price of Youku Tudou’s ADSs on October 15, 2015, one day preceding to the date that Youku Tudou declared it had received a “going private” proposal from Alibaba, and a premium of 49.9% to the volume-weighted average closing price of Youku Tudou’s ADSs during the three months preceding to October 15, 2015.
Youku Tudou’s board of directors (the “Youku Tudou Board”), acting on the recommendation of an independent special committee of the Youku Tudou Board (the “Special Committee”), unanimously approved the merger agreement and the Transaction and recommends that Youku Tudou’s shareholders vote to authorize and approve the merger agreement and the Transaction.
Youku Tudou Inc. operates as an Internet television company in the People’s Republic of China. Its Internet television platform enables users to search, view, and share video content across various devices.